An add-on therapy for treating kidney cancer patients has been launched in the UK.
Bevacizumab (Avastin) is a first-line treatment for patients with advanced renal cell cancer in combination with interferon.
Its manufacturer, Roche, said the drug combination doubled progression free survival from a median of 5.4 months with interferon alone to 10.2 months. Overall survival data is still being collected, the company said.
NICE guidance on renal cell carcinoma is expected in January 2009.